Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132410 | 1.00 | KDM4E (0.48) | KDM4EMAPTCDC7ERN1L3MBTL1 | |
| Formic Acid SCHEMBL28115076 | 0.91 | ERN1 (0.50) | KDM4EMAPTCDC7ERN1L3MBTL1 | |
| Formic Acid Methyl Ester SCHEMBL19808817 | 0.85 | ERN1 (0.45) | KDM4EMAPTCDC7ERN1L3MBTL1 | |
| SCHEMBL2009557 | 0.75 | MAPT (0.48) | KDM4EMAPTERN1L3MBTL1NPC1 | |
| SCHEMBL4054161 | 0.75 | MAPT (0.48) | KDM4EMAPTERN1L3MBTL1NPC1 | |
| SCHEMBL1062528 | 0.75 | HSP90AA1 (0.52) | KDM4EMAPTL3MBTL1NPC1LMNA | |
| SCHEMBL19445098 | 0.75 | MAPT (0.48) | KDM4EMAPTERN1L3MBTL1NPC1 | |
| SCHEMBL16460817 | 0.75 | KDM4E (0.48) | KDM4EMAPTL3MBTL1NPC1LMNA | |
| SCHEMBL276306 | 0.75 | MAPT (0.48) | KDM4EMAPTERN1L3MBTL1NPC1 | |
| SCHEMBL18583711 | 0.75 | KDM4E (0.48) | KDM4EMAPTERN1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275881-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2021-08-04 | — | — | EP | claimed |
| CN-106146491-A | 5-hydroxyl-1,7-naphthyridine compounds, its preparation method and the pharmaceutical applications thereof being optionally substituted aryl or heteroaryl | 沈阳三生制药有限责任公司 | 2016-11-23 | — | — | CN | claimed |
| EP-3835300-B1 | 1,7-NAPHTHYRIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREFOR | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2025-02-19 | — | — | EP | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023027098-A1 | ANTI–HEPATITIS B VIRUS AGENT AND USE FOR SAME | 国立大学法人北海道大学 | 2023-03-02 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-108884047-B | Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation | 沈阳三生制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-108884047-B | Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation | 沈阳三生制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-108884047-B | Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation | 沈阳三生制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3275881-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3287456-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20060058360-A1 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2006-03-16 | — | — | US | disclosed |
| EP-1567501-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004043931-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6730682-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2004-05-04 | — | — | US | disclosed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | KDM4E 201/4885MAPT 4388/4885CDC7 437/4885 |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | KDM4E 201/4885MAPT 4388/4885CDC7 437/4885 |
| US-20060058360-A1 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ADRB3, SLC6A2, SLC6A3 | KDM4E 4193/4885MAPT 3207/4885CDC7 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.